A shortage of the epilepsy medication SABRIL® (vigabatrin) powder for oral solution, specifically the 500 mg sachet/powder formulation, has been officially confirmed in Canada. According to the Drug Shortages Canada database, this shortage began on September 26, 2025, and is expected to last until approximately January 31, 2026.

While this shortage affects the powder/sachet form, the 500 mg tablet form of SABRIL remains on the market and may be considered as an alternative by prescribers according to the Canadian Epilepsy Alliance.

What You Can  Do

If you or someone you support is affected by this shortage, please consider the following steps:

• Check your supply: Monitor how much SABRIL powder you have left, and whether you have enough to last while a resolution is underway.
• Talk to your healthcare provider or pharmacist: Discuss whether switching to the tablet form is feasible, or whether other treatment adjustments may be appropriate.
• Explore contingency planning: Work with your care team to plan in case shortages deepen. This may include alternative medications (if clinically appropriate) or strategies to extend your supply.
• Share with us: We, along with the Canadian Epilepsy Alliance and other provincial agencies, are tracking this issue. The more we know how many people are affected, the stronger our collective voice can be in urging timely solutions. Please write to us at [email protected] and CC [email protected] with your experiences and supply concerns.

Further Resources

Product information: Canadian SABRIL monograph:
https://www.lundbeck.com/content/dam/lundbeck-com/ca/en/products/pdfs/Sabril_PM_EN.pdf

Questions about the medication? Contact Lundbeck Canada:

• Email: [email protected]
• Phone: 1-866-880-4636

Please do not discontinue or change your medication regimen without consulting your neurologist or epilepsy care team and reach out to us if there is anything our organization can do to support you during this period.